<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00847314</url>
  </required_header>
  <id_info>
    <org_study_id>13899</org_study_id>
    <secondary_id>NE0602</secondary_id>
    <nct_id>NCT00847314</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Testogel/Nebido in Combination With Exercise and Diet in Hypogonadal Male Patients</brief_title>
  <official_title>Efficacy and Tolerability of TestogelÂ® / Nebido in Combination With a Standardised Exercise and Diet Programme in Hypogonadal Male Patients With Abdominal Obesity Compared With Exercise and Diet Programme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With advancing age testosterone levels decline in men. Low testosterone levels plus certain
      symptoms are called &quot;Late Onset Hypogonadism (LOH)&quot;. Adipose tissue may contribute to
      testosterone deficiency. On the other hand testosterone deficiency again leads to a decrease
      in lean body mass and an increase in fat mass - one of the clinical signs / symptoms of LOH.
      Lifestyle changes (diet, exercise) alone or in combination with testosterone replacement
      (TRT), have an influence on the symptoms of LOH. The aim of this study is to assess the
      additional impact of TRT on Aging Male Symptom Score (AMS) and adiposity (waist
      circumference) in patients, who are on a diet and exercise program.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>At each visit</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Undeconate (Nebido-R, BAY86-5037)</intervention_name>
    <description>Male patients &gt; 35yrs in medical practices fulfilling all criteria for documentation.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male patients in medical practices &gt; 35yrs fulfilling all criteria for documentation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients &gt; 35yrs

          -  Waist Circumference &gt; 102cm

          -  Clinically and biochemically confirmed hypogonadism (testosterone group)

          -  Willingness to attempt weight optimization

        Exclusion Criteria:

          -  Androgen dependent carcinoma of the prostate or male mammary gland, past or present
             history of liver tumours

          -  hypersensitivity towards the active pharmaceutical ingredient or other ingredients.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many locations</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2009</study_first_submitted>
  <study_first_submitted_qc>February 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2009</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <responsible_party>
    <name_title>Medical Director</name_title>
    <organization>Bayer Schering Pharma AG</organization>
  </responsible_party>
  <keyword>Hypogonadism</keyword>
  <keyword>Abdominal obesity</keyword>
  <keyword>Physical exercise</keyword>
  <keyword>Testosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

